A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Carcinoma, Non-Small-Cell Lung
DRUG: MORAb-202
Incidence of treatment-related adverse events (TRAEs) leading to study treatment discontinuation, Up to 2 years|Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per investigator assessment, Up to 2 years
Number of participants with adverse events (AEs), Up to 2 years|Number of participants with serious adverse events (SAEs), Up to 2 years|Number of participants with treatment related AEs and SAEs, Up to 2 years|Number of participants with AEs of special interest (AESI), Up to 2 years|Number of deaths, Up to 2 years|Number of participants with clinical laboratory abnormalities, Up to 2 years|Progression-free Survival (PFS) by RECIST 1.1 per investigator assessment, Up to 2 years|Disease Control Rate (DCR) by RECIST 1.1 per investigator assessment, Up to 2 years|Duration of Response (DoR) by RECIST 1.1 per investigator assessment, Up to 2 years
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.